NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...

The ALS Association urges Congress to act swiftly to pass the ACT for ALS Reauthorization Act and sustain the momentum toward ...

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

A scientist diagnosed with an ultra-rare form of ALS linked to a CHCHD10 gene mutation is now enrolled in a one-of-a-kind ...

ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.

Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...

─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in ...

Add Yahoo as a preferred source to see more of our stories on Google. Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com (MAXIMUM ...

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical ...

Pennington Biomedical’s Dr. Jeff Keller and Dr. Aron Culotta of Tulane to lead collaboration of AI researchers, neuroscientist and drug developers Answer ALS is proud to announce the launch of a ...

After a period of clinical recalibration, the ALS and FTD field is regaining momentum, driven by a deeper biological understanding, more refined translational strategies, and continued industry ...